Converting molecular profiles of myeloid cells into biomarkers for inflammation and cancer

COST action No.
CA20117
Acronyme
Mye-InfoBank
Implementation period
06/10/2021- 05/10/2025
Representative of Latvia
Dr. Marina Makrecka-Kūka
Summary

Myeloid immune cells are important mediators in the pathology of many diseases, especially in diseases associated with chronic inflammation (DACI). Recent advancements in molecular profiling technologies have led to the generation of large data sets, many of those not fully explored yet, but accessible to the entire scientific community via public data repositories. It is the aim of this COST Action to repurpose those data sets, retrieve and curate myeloid cell-specific information, and apply this information to develop novel biomarkers for DACI. To this end, Mye-InfoBank will utilise COST networking tools to enable the interaction of molecular biologists, bioinformaticians, immunobiologists, biobank coordinators and clinicians. The concerted activity of these experts on myeloid cell biology (either basic or clinical research) MYE, bioinformatics INFO, and bio-banking BANK, will transform complex molecular information into standardised and applicable biomarkers, which have the potential to improve clinical decision making in a number of socio-economically important diseases.

COST  is supported by the EU Framework Programme Horizon 2020